Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...